Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.73 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281597 | 0.84 | SCN9A (1.00) | SCN9A | |
| SCHEMBL5431005 | 0.83 | SCN9A (0.68) | SCN9ACSNK2BCSNK2A1MEN1KMT2A | |
| SCHEMBL4903741 | 0.80 | SCN9A (0.73) | SCN9A | |
| SCHEMBL4596915 | 0.78 | SCN9A (0.63) | SCN9ACSNK2BCSNK2A1MEN1KMT2A | |
| SCHEMBL561973 | 0.73 | SCN9A (0.69) | SCN9A | |
| SCHEMBL4596851 | 0.71 | SCN9A (0.75) | SCN9A | |
| SCHEMBL281769 | 0.71 | SCN9A (0.75) | SCN9AMEN1KMT2A | |
| SCHEMBL282036 | 0.70 | SCN9A (0.74) | SCN9AMEN1KMT2A | |
| SCHEMBL4597321 | 0.68 | SCN9A (0.71) | SCN9A | |
| SCHEMBL4732218 | 0.68 | SCN9A (0.67) | SCN9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | claimed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | SCN9A 148/4885CSNK2B 1340/4885CSNK2A1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.